ClinicalTrials.gg
RecruitingNCT05258396REMYELIKIDSUpdated Mar 6, 2026

Exploring Cortical Remyelination in Children With Multiple Sclerosis

An interventional study of MRI without injection of contrast product in Children With Multiple Sclerosis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 3 sites in France. Open to participants aged 12 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Multiple Sclerosis by Assistance Publique - Hôpitaux de Paris — 8 open to participants now, 8 under way, 1 of them phase 3. Multiple Sclerosis · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
15th of 16
40 · median 74
Started
2022
with 4 others
No phase
13 of 23
4 open now
Registered
16th of 23
by date

Among the 23 studies in Multiple Sclerosis by Assistance Publique - Hôpitaux de Paris, this one is the 15th largest by planned enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2022, is one of 13 with no phase, and was the 16th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

8 of the 23 studies in Multiple Sclerosis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Multiple Sclerosis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Multiple sclerosis (MS) in children, a rare disease, follows a relapsing remitting course with a shorter interval between the first 2 clinical events and higher annualized relapse rate as compared with MS in adults. Residual deficits following clinical events are less frequent. The vast majority of children and adolescents with MS are thought to have a greater potential for myelin repair than adults. However convincing data in the literature to support this hypothesis are lacking, because until now no imaging technique has been validated to measure remyelination in vivo.

Read the detailed description

Multiple sclerosis (MS) in children, a rare disease, follows a relapsing remitting course with a shorter interval between the first 2 clinical events and higher annualized relapse rate as compared with MS in adults. Residual deficits following clinical events are less frequent. The vast majority of children and adolescents with MS are thought to have a greater potential for myelin repair than adults. However convincing data in the literature to support this hypothesis are lacking, because until now no imaging technique has been validated to measure remyelination in vivo.

The investigator team has performed a first study to generate for the first time magnetization transfer ratio (MTR)-based maps of cortical myelin repair in 15 adult patients with MS. The team found that patients with MS showed a high variability in cortical myelin repair, with variable index of cortical remyelination. Moreover, there was a significant correlation between the index of cortical remyelination and clinical scores.

Even if childhood onset MS take longer to reach states of irreversible disability, severe disability will eventually occur at a young age. Moreover, pediatric MS could be responsible for cognitive disorders.

It is therefore of crucial relevance to develop research programs designed to generate novel imaging techniques to measure the efficacy of remyelinating therapies. Multiple sclerosis (MS) in children, a rare disease, follows a relapsing remitting course with a shorter interval between the first 2 clinical events and higher annualized relapse rate as compared with MS in adults. Residual deficits following clinical events are less frequent. The vast majority of children and adolescents with MS are thought to have a greater potential for myelin repair than adults. However convincing data in the literature to support this hypothesis are lacking, because until now no imaging technique has been validated to measure remyelination in vivo.

The team has performed a first study to generate for the first time magnetization transfer ratio (MTR) - based maps of cortical myelin repair in 15 adult patients with MS. The investigator team found that patients with MS showed a high variability in cortical myelin repair, with variable index of cortical remyelination. Moreover, there was a significant correlation between the index of cortical remyelination and clinical scores.

Even if childhood onset MS take longer to reach states of irreversible disability, severe disability will eventually occur at a young age. Moreover, pediatric MS could be responsible for cognitive disorders.

It is therefore of crucial relevance to develop research programs designed to generate novel imaging techniques to measure the efficacy of remyelinating therapies.

Finally, another extremely challenging issue in the care of children with MS is the difficulty of the transition between pediatric and adult care. Over last years, at the Pitié-Salpêtrière Hospital, the neurology team created a transition program called JUMP to improve medical, educational and psychosocial outcome for adolescent patients with MS .Taking part in the present study, young patients from 16 to 18 years old could have a direct access to the JUMP program, with the coordination of the dedicated nurses.

03

Conditions studied

  • Children With Multiple Sclerosis

Browse trials for

Keywords

  • MRI
  • MS
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for patients :

  • age between 12 years old and 18 years old
  • RR-MS defined by 2017 McDonald criteria
  • no relapse the last 4 weeks
  • no methylprednisolone or prednisolone the last 4 weeks.
  • affiliated to the social security system
  • signature of the consent by the 2 holders of parental authority

Inclusion Criteria for Volunteers:

  • age between 12 years old and 18 years old
  • absence of any neurological
  • signature of the consent by the 2 holders of parental authority

Exclusion Criteria for both groups:

  • Parental rejection
  • Contre-indication of brain MRI: pace maker, tatoo of the face, claustrophobia….
  • Pregnancy, copper intrauterine device
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Patients with MS

    Children with MS

    Other: MRI without injection of contrast product

  • Experimental
    Volunteers

    matched in age and sex with patients. Volunteers will perform only one brain MRI, as requested by the neurologist

    Other: MRI without injection of contrast product

Interventions

  • OtherMRI without injection of contrast product

    MRI without injection of contrast product

06

What researchers measure

Primary outcomes

  1. MTR-based individual indices

    To investigate the association between MTR-based individual indices of cortical myelin repair in children with MS and one cognitive score (Symbol Digital Modalities Test (SDMT)) at baseline

    Time frame: 1 day

Secondary outcomes

  1. indices of cortical remyelination

    To investigate the association between individual indices of cortical remyelination and neurological disability

    Time frame: 6 months

07

Study locations

2 of 3 sites recruiting
  • Service de Neurologie Pédiatrique, Hôpital du Kremlin Bicêtre
    Le Kremlin-Bicêtre, 94270, France
    Recruiting
  • CIC Neurosciences - Pitié Salpêtrière
    Paris, 75013, France
    Recruiting
  • Service de Neurologie, GH Pitié Salpêtrière
    Paris, 75013, France
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Sep 2026, 49 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 49 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2022
First posted
Feb 28, 2022
StartActual
Aug 11, 2022
Primary completionEst.
Sep 11, 2026
CompletionEst.
Sep 11, 2026
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05258396
Responsible party
Sponsor
First posted
Feb 28, 2022
Start date
Aug 11, 2022
Primary completion
Sep 11, 2026 (estimated)
Completion
Sep 11, 2026 (estimated)
Last update
Mar 6, 2026

Study contacts

Elisabeth Maillart, MD, PH
Contact
elisabeth.maillart@aphp.fr
1 42 16 19 75 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion